<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001755237="http://www.cyclerion.com/20251231"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ck0001755237-20251231.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P07_28_2023To07_28_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2023-07-28</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="P08_01_2024To08_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="P05_01_2024To05_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="P07_22_2024To07_22_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2024-07-22</startDate>
            <endDate>2024-07-22</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn02_04_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2025-02-04</instant>
        </period>
    </context>
    <context id="P05_07_2025To05_07_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_OptionAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_LicenseAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PurchaseAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ck0001755237:InterestAndOtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:CyclerionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_OptionAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_LicenseAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PurchaseAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:PatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ck0001755237:InterestAndOtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaMaterialPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001755237:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis_SalesAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001755237:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_13_2024To12_13_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:CyclerionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-13</startDate>
            <endDate>2024-12-13</endDate>
        </period>
    </context>
    <context id="P12_01_2025To12_01_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-01</endDate>
        </period>
    </context>
    <context id="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ck0001755237:TisentoTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_MinimumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:WeightedAverageInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_MinimumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:TerminalDeclineRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_TreasuryRateMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:TreasuryRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_MaximumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:WeightedAverageInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_MaximumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:TerminalDeclineRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001755237:TwoThousandTwentyFiveEquityPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P03_21_2025To03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001755237:TwoThousandTwentyFiveEquityPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001755237:TwoThousandTwentyFiveEquityPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="PAsOn05_07_2025_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-07</instant>
        </period>
    </context>
    <context id="P09_19_2025To09_19_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:PatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-19</startDate>
            <endDate>2025-09-19</endDate>
        </period>
    </context>
    <context id="P06_03_2021To06_03_2021_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-03</startDate>
            <endDate>2021-06-03</endDate>
        </period>
    </context>
    <context id="P06_03_2021To06_03_2021_AkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-03</startDate>
            <endDate>2021-06-03</endDate>
        </period>
    </context>
    <context id="P01_01_2025To09_30_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="P02_01_2026To02_28_2026_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="P01_03_2026To01_03_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-03</startDate>
            <endDate>2026-01-03</endDate>
        </period>
    </context>
    <context id="PAsOn01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-06</instant>
        </period>
    </context>
    <context id="P01_06_2026To01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-06</startDate>
            <endDate>2026-01-06</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="P01_01_2025To12_31_2025" id="ixv-45765">0001755237</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="P01_01_2025To12_31_2025" id="ixv-45766">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="P01_01_2025To12_31_2025" id="ixv-46642">S-4</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2025To12_31_2025" id="ixv-46643">CYCLERION THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2025To12_31_2025" id="ixv-46644">MA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2025To12_31_2025" id="ixv-46645">2834</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2025To12_31_2025" id="ixv-46646">83-1895370</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2025To12_31_2025" id="ixv-99">245 First Street, 18th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2025To12_31_2025" id="ixv-46647">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2025To12_31_2025" id="ixv-46648">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2025To12_31_2025" id="ixv-46649">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2025To12_31_2025" id="ixv-46650">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2025To12_31_2025" id="ixv-46651">327-8778</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2025To12_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-46652">Regina Graul, Ph.D.</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2025To12_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-119">245 First Street, 18th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2025To12_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-46653">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2025To12_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-46654">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2025To12_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-46655">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2025To12_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-46656">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2025To12_31_2025_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-46657">327-8778</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2025To12_31_2025" id="ixv-46658">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2025To12_31_2025" id="ixv-46659">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2025To12_31_2025" id="ixv-46660">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:DefinedContributionPlanTypeExtensibleList contextRef="P01_01_2025To12_31_2025" id="hidden162598875">http://fasb.org/us-gaap/2025#QualifiedPlanMember</us-gaap:DefinedContributionPlanTypeExtensibleList>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46666"
      unitRef="Unit_USD">3240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46667"
      unitRef="Unit_USD">3232000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46668"
      unitRef="Unit_USD">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46669"
      unitRef="Unit_USD">556000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46670"
      unitRef="Unit_USD">384000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46671"
      unitRef="Unit_USD">421000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46672"
      unitRef="Unit_USD">11000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46673"
      unitRef="Unit_USD">16000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46674"
      unitRef="Unit_USD">4635000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46675"
      unitRef="Unit_USD">4225000</us-gaap:AssetsCurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46676"
      unitRef="Unit_USD">5350000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46677"
      unitRef="Unit_USD">5350000</us-gaap:OtherLongTermInvestments>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46678"
      unitRef="Unit_USD">9985000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46679"
      unitRef="Unit_USD">9575000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46680"
      unitRef="Unit_USD">508000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46681"
      unitRef="Unit_USD">390000</us-gaap:AccountsPayableCurrent>
    <ck0001755237:AccruedResearchAndDevelopmentCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46682"
      unitRef="Unit_USD">198000</ck0001755237:AccruedResearchAndDevelopmentCurrent>
    <ck0001755237:AccruedResearchAndDevelopmentCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46683"
      unitRef="Unit_USD">52000</ck0001755237:AccruedResearchAndDevelopmentCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46684"
      unitRef="Unit_USD">194000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46685"
      unitRef="Unit_USD">283000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46686"
      unitRef="Unit_USD">900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46687"
      unitRef="Unit_USD">725000</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46688"
      unitRef="Unit_USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46689"
      unitRef="Unit_USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-46690"
      unitRef="Unit_USD_per_Share">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-46691"
      unitRef="Unit_USD_per_Share">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-46692"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-46693"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-46694"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-46695"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-46696"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2024_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-46697"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46698"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46699"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-46700"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-46701"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-46702"
      unitRef="Unit_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-46703"
      unitRef="Unit_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-46704"
      unitRef="Unit_shares">3925314</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-46705"
      unitRef="Unit_shares">2710096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-46706"
      unitRef="Unit_shares">3821236</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-46707"
      unitRef="Unit_shares">2545922</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46708"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46709"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46710"
      unitRef="Unit_USD">280105000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46711"
      unitRef="Unit_USD">276342000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46712"
      unitRef="Unit_USD">-271020000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46713"
      unitRef="Unit_USD">-267492000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46714"
      unitRef="Unit_USD">9085000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46715"
      unitRef="Unit_USD">8850000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46716"
      unitRef="Unit_USD">9985000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46717"
      unitRef="Unit_USD">9575000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025_LicenseAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-46718"
      unitRef="Unit_USD">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024_LicenseAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-46719"
      unitRef="Unit_USD">1750000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025_PurchaseAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-46720"
      unitRef="Unit_USD">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024_PurchaseAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-46721"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025_OptionAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-46722"
      unitRef="Unit_USD">274000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024_OptionAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-46723"
      unitRef="Unit_USD">250000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46724"
      unitRef="Unit_USD">2074000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46725"
      unitRef="Unit_USD">2000000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46726"
      unitRef="Unit_USD">959000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46727"
      unitRef="Unit_USD">286000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46728"
      unitRef="Unit_USD">6088000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46729"
      unitRef="Unit_USD">5342000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46730"
      unitRef="Unit_USD">7047000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46731"
      unitRef="Unit_USD">5628000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46732"
      unitRef="Unit_USD">-4973000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46733"
      unitRef="Unit_USD">-3628000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46734"
      unitRef="Unit_USD">128000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46735"
      unitRef="Unit_USD">208000</us-gaap:OtherNonoperatingIncome>
    <ck0001755237:GainLossFromSettlementOfAccountPayable
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46736"
      unitRef="Unit_USD">0</ck0001755237:GainLossFromSettlementOfAccountPayable>
    <ck0001755237:GainLossFromSettlementOfAccountPayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46737"
      unitRef="Unit_USD">363000</ck0001755237:GainLossFromSettlementOfAccountPayable>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46738"
      unitRef="Unit_USD">1317000</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46739"
      unitRef="Unit_USD">0</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46740"
      unitRef="Unit_USD">1445000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46741"
      unitRef="Unit_USD">571000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46742"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46743"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-46744"
      unitRef="Unit_USD_per_Share">-1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-46745"
      unitRef="Unit_USD_per_Share">-1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-46746"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-46747"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46748"
      unitRef="Unit_shares">3181000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46749"
      unitRef="Unit_shares">3181000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46750"
      unitRef="Unit_shares">2518000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46751"
      unitRef="Unit_shares">2518000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46752"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46753"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46754"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46755"
      unitRef="Unit_USD">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46756"
      unitRef="Unit_USD">-3528000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46757"
      unitRef="Unit_USD">-3063000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-46758"
      unitRef="Unit_shares">2474159</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-46759"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46760"
      unitRef="Unit_USD">275717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46761"
      unitRef="Unit_USD">-264417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46762"
      unitRef="Unit_USD">-12000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-46763"
      unitRef="Unit_USD">11288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46764"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46765"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-46766"
      unitRef="Unit_shares">71763</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46767"
      unitRef="Unit_USD">625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46768"
      unitRef="Unit_USD">625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2024To12_31_2024_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46769"
      unitRef="Unit_USD">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46770"
      unitRef="Unit_USD">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment
      contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46771"
      unitRef="Unit_USD">-18000</ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment>
    <ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment
      contextRef="P01_01_2024To12_31_2024_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46772"
      unitRef="Unit_USD">18000</ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46773"
      unitRef="Unit_shares">2545922</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46774"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46775"
      unitRef="Unit_USD">276342000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46776"
      unitRef="Unit_USD">-267492000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46777"
      unitRef="Unit_USD">8850000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare
      contextRef="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-46778"
      unitRef="Unit_shares">499998</ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare>
    <ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue
      contextRef="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46779"
      unitRef="Unit_USD">1245000</ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue>
    <ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46780"
      unitRef="Unit_USD">1245000</ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-46781"
      unitRef="Unit_shares">715220</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46782"
      unitRef="Unit_USD">2077000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46783"
      unitRef="Unit_USD">2077000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46784"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46785"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-46786"
      unitRef="Unit_shares">60096</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46787"
      unitRef="Unit_USD">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46788"
      unitRef="Unit_USD">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46789"
      unitRef="Unit_shares">3821236</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46790"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46791"
      unitRef="Unit_USD">280105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-46792"
      unitRef="Unit_USD">-271020000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46793"
      unitRef="Unit_USD">9085000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46794"
      unitRef="Unit_USD">-3528000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46795"
      unitRef="Unit_USD">-3057000</us-gaap:ProfitLoss>
    <ck0001755237:GainLossFromSettlementOfAccountPayable
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46796"
      unitRef="Unit_USD">0</ck0001755237:GainLossFromSettlementOfAccountPayable>
    <ck0001755237:GainLossFromSettlementOfAccountPayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46797"
      unitRef="Unit_USD">363000</ck0001755237:GainLossFromSettlementOfAccountPayable>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46798"
      unitRef="Unit_USD">441000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46799"
      unitRef="Unit_USD">625000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46800"
      unitRef="Unit_USD">444000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46801"
      unitRef="Unit_USD">556000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46802"
      unitRef="Unit_USD">-37000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46803"
      unitRef="Unit_USD">-21000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46804"
      unitRef="Unit_USD">-5000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46805"
      unitRef="Unit_USD">5000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46806"
      unitRef="Unit_USD">118000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46807"
      unitRef="Unit_USD">-445000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46808"
      unitRef="Unit_USD">146000</ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment>
    <ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46809"
      unitRef="Unit_USD">-38000</ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46810"
      unitRef="Unit_USD">-89000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46811"
      unitRef="Unit_USD">-515000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46812"
      unitRef="Unit_USD">-3314000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46813"
      unitRef="Unit_USD">-4333000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ck0001755237:ProceedsFromAtTheOffer
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46814"
      unitRef="Unit_USD">2077000</ck0001755237:ProceedsFromAtTheOffer>
    <ck0001755237:ProceedsFromAtTheOffer
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46815"
      unitRef="Unit_USD">0</ck0001755237:ProceedsFromAtTheOffer>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46816"
      unitRef="Unit_USD">1375000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46817"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001755237:IssuanceCostsPaidForPrivatePlacement
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46818"
      unitRef="Unit_USD">-130000</ck0001755237:IssuanceCostsPaidForPrivatePlacement>
    <ck0001755237:IssuanceCostsPaidForPrivatePlacement
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46819"
      unitRef="Unit_USD">0</ck0001755237:IssuanceCostsPaidForPrivatePlacement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46820"
      unitRef="Unit_USD">3322000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46821"
      unitRef="Unit_USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46822"
      unitRef="Unit_USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46823"
      unitRef="Unit_USD">-6000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46824"
      unitRef="Unit_USD">8000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46825"
      unitRef="Unit_USD">-4339000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46826"
      unitRef="Unit_USD">3232000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-46827"
      unitRef="Unit_USD">7571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46828"
      unitRef="Unit_USD">3240000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46829"
      unitRef="Unit_USD">3232000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-28980"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;1. Nature of Business &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Nature of Operations &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Cyclerion Therapeutics, Inc. (&#x201c;Cyclerion&#x201d;, the &#x201c;Company&#x201d; or &#x201c;we&#x201d;) became an independent public company on April&#160;1, 2019 after Ironwood Pharmaceuticals, Inc. completed a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;tax-free&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;spin-off&lt;/div&gt; of their sGC business. Cyclerion has one employee as of December&#160;31, 2025 and also relies on a team of specialist consultants for its operations. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Cyclerion is focused on building a new pipeline of innovative therapeutics to address serious neuropsychiatric diseases. The Company&#x2019;s current strategic focus is centered on the development of a novel therapeutic approach for treatment-resistant depression (&#x201c;TRD&#x201d;), which represents a substantial clinical and commercial opportunity. Over the past year, the Company has refined its strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, Cyclerion has evaluated multiple opportunities and prioritized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CYC-126,&lt;/div&gt; an individualized therapy for TRD as its foundational development program. In September 2025, the Company entered into a license agreement with the Massachusetts Institute of Technology (&#x201c;MIT&#x201d;) for intellectual property supporting this program (see Note 11), and in January 2026 entered into a collaboration and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;option-to-license&lt;/div&gt;&lt;/div&gt; agreement with Medsteer SAS (&#x201c;Medsteer&#x201d;) to access certain technology, data assets, and technical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; related to drug delivery and physiological monitoring. The Company is advancing development planning, regulatory strategy, and commercial positioning for this program and intends to initiate a Phase 2 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;proof-of-concept&lt;/div&gt;&lt;/div&gt; study in Australia in the second half of 2026. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In parallel with the advancement of its neuropsychiatric strategy, Cyclerion continues to evaluate opportunities related to its legacy soluble guanylate cyclase (&#x201c;sGC&#x201d;) stimulator assets, including potential collaborations, monetization opportunities, or other strategic transactions designed to maximize shareholder value. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June&#160;3, 2021, Cyclerion entered into a license agreement with Akebia Therapeutics Inc. (&#x201c;Akebia&#x201d;) relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other related products and forms thereof enumerated in such agreement. In 2021, Akebia paid a&#160;$3.0 million&#160;upfront payment to the Company upon signing of the license agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On December&#160;13, 2024, Cyclerion announced that Cyclerion and Akebia have &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-negotiated&lt;/div&gt; a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator.&#160;Under this new license amendment, Cyclerion will receive&#160;$1.75 million&#160;in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million was received in September 2025. In addition, Akebia is responsible for all intellectual property expenses associated with praliciguat. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated (defined as first patient dosed) Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis&#160;(&#x201c;FSGS&#x201d;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to us and it was received in February 2026. The Company is eligible to receive additional milestone cash payments of up to approximately&#160;$557.5 million&#160;in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher-tiered sales-based royalties ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-single-digits&lt;/div&gt; to twenty percent. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#x201c;Option Agreement&#x201d;) with a third party (the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;Optionee&#x201d;), pursuant to which the Optionee had an option (the &#x201c;Option&#x201d;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company is currently exploring potential license opportunities for olinciguat. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Zagociguat is a clinical-stage &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CNS-penetrant&lt;/div&gt; sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY3018 is a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CNS-targeted&lt;/div&gt; sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. On July&#160;28, 2023, the Company sold Zagociguat and CY3018 to Tisento Therapeutics, Inc. (&#x201c;Tisento&#x201d;), a newly formed private company focused on their development, in exchange for $8.0&#160;million in cash consideration, $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 for the period between signing and closing of the transaction, and 10% of all of Tisento&#x2019;s parent&#x2019;s outstanding equity securities (&#x201c;Tisento Parent&#x201d;). &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Cyclerion GmbH, a wholly owned subsidiary, was incorporated in Zug, Switzerland on May&#160;3, 2019. The functional currency is the Swiss franc. Cyclerion GmbH was liquidated and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;de-registered&lt;/div&gt; in May 2024. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cyclerion Securities Corporation, a wholly owned subsidiary, was incorporated in Massachusetts on November&#160;15, 2019 and was granted securities corporation status in Massachusetts. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Purchase Agreement &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In March 2023, the Company entered into a stock purchase agreement with the Company&#x2019;s former Chief Executive Officer (the &#x201c;CEO&#x201d;) pursuant to which he invested $5&#160;million in cash for 225,000 shares of common stock and 351,037 shares of Series A Convertible Preferred Stock of the Company at a price of $8.68 per share (after giving effect to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;1-for-20&lt;/div&gt;&lt;/div&gt; reverse stock split the Company implemented on May&#160;15, 2023). The Series A Convertible Preferred Stock is convertible into shares of the Company&#x2019;s common stock on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;one-to-one&lt;/div&gt;&lt;/div&gt; basis. The closing of the equity investment took place on May&#160;19, 2023, and (to comply with Nasdaq listing requirements) the Company&#x2019;s shareholders approved such convertibility on July&#160;19, 2023. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2025 Equity Private Placement &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On March&#160;21, 2025, the Company entered into a Stock Purchase Agreement (the &#x201c;2025 Equity Private Placement&#x201d;) for a private placement of 499,998 shares of the Company&#x2019;s common stock, at a purchase price of $2.75 per share for total gross proceeds of approximately $1.375&#160;million. The closing of the 2025 Equity Private Placement occurred on March&#160;25, 2025. The Company incurred transaction costs of $0.1&#160;million for the 2025 Equity Private Placement. The Shares issued were not registered under the Securities Act of 1933, as amended, or any state securities laws and will be issued pursuant to the exemption from registration provided for under Section&#160;4(a)(2) of the Securities Act as a transaction not involving a public offering. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the 2025 Equity Private Placement, the Company entered into a Registration Rights Agreement with the investors, dated March&#160;21, 2025, pursuant to which the Company agreed to register the resale of the Shares pursuant to a registration statement which was filed with the SEC and declared effective by the SEC on May&#160;15, 2025. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;At-the-Market&lt;/div&gt;&lt;/div&gt; Offering &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On February&#160;4, 2025, the Company filed a Registration Statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-3&lt;/div&gt; (the &#x201c;Shelf&#x201d;) with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) in relation to the registration of common stock, preferred &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;stock, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $25.0&#160;million.&#160;The Registration Statement was declared effective by the SEC in February 2025. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On May&#160;7, 2025, the Company and Guggenheim Securities, LLC (&#x201c;Guggenheim Securities&#x201d;) entered into a Sales Agreement (the &#x201c;Sales Agreement&#x201d;), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the &#x201c;Shares&#x201d;), having an aggregate offering price of up to $20,000,000 from time to time through or to Guggenheim Securities, acting as the Company&#x2019;s agent, subject to the application of General Instruction I.B.6 of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Form&#160;S-3&#160;(&#x201c;Instruction&lt;/div&gt; I.B.6&#x201d;) pertaining to primary offerings by certain registrants, including the Company. The Company has provided Guggenheim Securities with customary indemnification rights, and the Company will pay Guggenheim Securities cash commission of 3.0% of the gross proceeds of the Shares sold under the Sales Agreement. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the year ended December&#160;31, 2025, the Company sold 715,220 shares of its common stock for net proceeds of $2.1&#160;million under the Sales Agreement, after deducting commissions paid to Guggenheim Securities of $0.1&#160;million. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#x2019;s financial position and the results of its operations for the fiscal years presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation and Cyclerion GmbH which was dissolved in May 2024. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At each reporting period, in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;205-40,&lt;/div&gt; Going Concern, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company&#x2019;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#x2019;s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1)&#160;it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2)&#160;it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;205-40,&lt;/div&gt; the future receipt of potential funding from future partnerships, equity or debt issuances, certain cost reduction measures and the potential milestones from the Akebia agreement cannot be considered probable at this time because these plans are not entirely within the Company&#x2019;s control and/or have not been approved by the Board of Directors as of the date of these consolidated financial statements. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company expects that its cash and cash equivalents as of December&#160;31, 2025, will be sufficient to fund operations through &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-2026,&lt;/div&gt; however the Company will need to obtain additional funding to sustain operations as it expects to continue to generate operating losses for the foreseeable future. The Company&#x2019;s expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations, raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s plans to alleviate the conditions that raise substantial doubt include reduced spending, and the pursuit of additional capital. Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. The accompanying financial statements &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;have &lt;/div&gt;been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. &lt;/div&gt; </us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_01_2021To12_31_2021_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46830"
      unitRef="Unit_USD">3000000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P12_13_2024To12_13_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-46831"
      unitRef="Unit_USD">1750000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-46832"
      unitRef="Unit_USD">1250000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:AdditionalUpFrontPayment
      contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46833"
      unitRef="Unit_USD">500000</ck0001755237:AdditionalUpFrontPayment>
    <ck0001755237:DevelopmentMilestonePayment
      contextRef="P12_01_2025To12_01_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46834"
      unitRef="Unit_USD">1000000</ck0001755237:DevelopmentMilestonePayment>
    <ck0001755237:PaymentOfCashMilestone
      contextRef="P01_01_2025To12_31_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-46835"
      unitRef="Unit_USD">557500000</ck0001755237:PaymentOfCashMilestone>
    <ck0001755237:OptionFee
      contextRef="P08_01_2024To08_31_2024"
      decimals="0"
      id="ixv-46837"
      unitRef="Unit_USD">150000</ck0001755237:OptionFee>
    <ck0001755237:SubsequentFees
      contextRef="P08_01_2024To08_31_2024"
      decimals="0"
      id="ixv-46838"
      unitRef="Unit_USD">80000</ck0001755237:SubsequentFees>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-46839"
      unitRef="Unit_USD">8000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:OperatingExpenses
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-46840"
      unitRef="Unit_USD">2400000</us-gaap:OperatingExpenses>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      id="ixv-46841"
      unitRef="Unit_pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      id="ixv-46842"
      unitRef="Unit_USD">5000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46843"
      unitRef="Unit_shares">225000</us-gaap:SharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-46844"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-46845"
      unitRef="Unit_USD_per_Share">8.68</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-46846"
      unitRef="Unit_shares">499998</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-46847"
      unitRef="Unit_USD_per_Share">2.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P03_21_2025To03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-46848"
      unitRef="Unit_USD">1375000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001755237:TransactionCostsSaleOfTransferredAssets
      contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-46849"
      unitRef="Unit_USD">100000</ck0001755237:TransactionCostsSaleOfTransferredAssets>
    <ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice
      contextRef="PAsOn02_04_2025"
      decimals="-5"
      id="ixv-46851"
      unitRef="Unit_USD">25000000</ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice>
    <ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice
      contextRef="PAsOn05_07_2025_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-46852"
      unitRef="Unit_USD">20000000</ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice>
    <ck0001755237:CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock
      contextRef="P05_07_2025To05_07_2025"
      decimals="3"
      id="ixv-46853"
      unitRef="Unit_pure">0.03</ck0001755237:CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-46854"
      unitRef="Unit_shares">715220</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-46855"
      unitRef="Unit_USD">2100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-46856"
      unitRef="Unit_USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29071"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#x2019;s financial position and the results of its operations for the fiscal years presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation and Cyclerion GmbH which was dissolved in May 2024. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. &lt;/div&gt;&lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29104"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.&#160;The Company&#x2019;s president and chief executive officer, who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews the Company&#x2019;s financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews net loss, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-operating&lt;/div&gt; expenses and operating expenses excluding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cash&lt;/div&gt; stock based compensation expense. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Variable Interest Entities &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, (ii)&#160;the parties&#x2019; contractual rights and responsibilities pursuant to any contractual agreements and (iii)&#160;which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements at the time that determination is made. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Investment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for an identical or a similar investment of the same issuer, the Company will measure the equity security at fair value as of the date that the observable transaction occurred in accordance with ASC Topic 321, Investments-Equity Securities. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires the Company&#x2019;s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, fair value determination of other investment, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period &lt;div style="display:inline;"&gt;in&lt;/div&gt; which they become known. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair Value of Investment Instruments &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;1 &#x2014; Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;2 &#x2014; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;3 &#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign Currency Translation Adjustment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The functional currency of the Company&#x2019;s former foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company&#x2019;s former foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company&#x2019;s former foreign subsidiary was included as a foreign currency translation adjustment in the consolidated statements of stockholders&#x2019; equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-measurement&lt;/div&gt; of intercompany balances are recorded in the consolidated statements of operations. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;significant outstanding invoices. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had &lt;div style="display:inline;"&gt;significant&lt;/div&gt; write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December&#160;31, 2025 or 2024. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 606&#x201d;), it performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1)&#160;license agreement, (2)&#160;purchase agreement and (3)&#160;option to license agreement which are fully described in Note 11, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License and Option Agreement&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and Administrative Expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel and outside consultants providing the Company&#x2019;s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company&#x2019;s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company is primarily subject to U.S. Federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;more-likely-than-not&#x201d;&lt;/div&gt; of being sustained by the applicable tax authority. Tax positions not deemed to meet a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;more-likely-than-not&lt;/div&gt; threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion&#x2019;s income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December&#160;31, 2025, and 2024. The Company&#x2019;s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December&#160;31, 2025 and 2024, the Company has no accruals for interest or penalties related to income tax matters. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $0.3&#160;million and $0.6&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Interest and Other Income, Net &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;For the year ended December&#160;31, 2025 and 2024, interest and other income, net consisted of a $0.1&#160;million and $0.2&#160;million of interest income related to interest generated from the Company&#x2019;s cash and cash equivalents balances, respectively. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company considers events or transactions that have occurred after the balance sheet date of December&#160;31, 2025, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K.&lt;/div&gt; See Note 12, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December&#160;31, 2025 and 2024, that had a material effect on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2025, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2025-05,&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326), which requires incremental disclosures on estimating expected credit losses. The Company will adopt this guidance beginning with its annual report for fiscal 2027. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-align: left; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-07,&lt;/div&gt; Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company adopted this guidance beginning with its annual report for fiscal 2025 and interim periods thereafter on a retrospective basis. The adoption did not have a material effect on the consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09,&lt;/div&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09&lt;/div&gt; requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. For entities other than PBEs, the requirements will be effective for annual periods beginning after December&#160;15, 2025. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December&#160;31, 2025 and continuing to provide the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-ASU&lt;/div&gt; disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December&#160;31, 2025, the Company adopted this new ASU and it only impacts the Company&#x2019;s income tax disclosures with no impact to its operations, cash flows, or financial condition. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#x2019;s consolidated financial statements upon adoption. &lt;/div&gt;&lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29107"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.&#160;The Company&#x2019;s president and chief executive officer, who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews the Company&#x2019;s financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews net loss, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-operating&lt;/div&gt; expenses and operating expenses excluding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cash&lt;/div&gt; stock based compensation expense. &lt;/div&gt; </us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="P01_01_2025To12_31_2025" id="ixv-29113"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Variable Interest Entities &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, (ii)&#160;the parties&#x2019; contractual rights and responsibilities pursuant to any contractual agreements and (iii)&#160;which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements at the time that determination is made. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made. &lt;/div&gt;&lt;/div&gt; </us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:InvestmentPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29118"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Investment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for an identical or a similar investment of the same issuer, the Company will measure the equity security at fair value as of the date that the observable transaction occurred in accordance with ASC Topic 321, Investments-Equity Securities. &lt;/div&gt;&lt;/div&gt; </us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2025To12_31_2025" id="ixv-29123"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires the Company&#x2019;s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, fair value determination of other investment, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period &lt;div style="display:inline;"&gt;in&lt;/div&gt; which they become known. &lt;/div&gt;&lt;/div&gt; </us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29150"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value. &lt;/div&gt;&lt;/div&gt; </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2025To12_31_2025" id="ixv-29155"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair Value of Investment Instruments &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;1 &#x2014; Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;2 &#x2014; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;3 &#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29193"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign Currency Translation Adjustment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The functional currency of the Company&#x2019;s former foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company&#x2019;s former foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company&#x2019;s former foreign subsidiary was included as a foreign currency translation adjustment in the consolidated statements of stockholders&#x2019; equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-measurement&lt;/div&gt; of intercompany balances are recorded in the consolidated statements of operations. &lt;/div&gt; </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <ck0001755237:RelatedPartyAccountsReceivablePolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29200"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;significant outstanding invoices. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had &lt;div style="display:inline;"&gt;significant&lt;/div&gt; write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December&#160;31, 2025 or 2024. &lt;/div&gt;&lt;/div&gt; </ck0001755237:RelatedPartyAccountsReceivablePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29227"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 606&#x201d;), it performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1)&#160;license agreement, (2)&#160;purchase agreement and (3)&#160;option to license agreement which are fully described in Note 11, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License and Option Agreement&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2025To12_31_2025" id="ixv-29235"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses. &lt;/div&gt;&lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29242"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and Administrative Expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel and outside consultants providing the Company&#x2019;s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company&#x2019;s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services. &lt;/div&gt;&lt;/div&gt; </us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29247"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company is primarily subject to U.S. Federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;more-likely-than-not&#x201d;&lt;/div&gt; of being sustained by the applicable tax authority. Tax positions not deemed to meet a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;more-likely-than-not&lt;/div&gt; threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion&#x2019;s income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December&#160;31, 2025, and 2024. The Company&#x2019;s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December&#160;31, 2025 and 2024, the Company has no accruals for interest or penalties related to income tax matters. &lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2024"
      decimals="-6"
      id="ixv-46861"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2025"
      decimals="-6"
      id="ixv-46862"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <ck0001755237:PatentCostsPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29276"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $0.3&#160;million and $0.6&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. &lt;/div&gt;&lt;/div&gt; </ck0001755237:PatentCostsPolicyTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2025To12_31_2025_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      id="ixv-46863"
      unitRef="Unit_USD">300000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2024To12_31_2024_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      id="ixv-46864"
      unitRef="Unit_USD">600000</us-gaap:ProfessionalFees>
    <ck0001755237:InterestAndOtherIncomePolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29281"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Interest and Other Income, Net &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;For the year ended December&#160;31, 2025 and 2024, interest and other income, net consisted of a $0.1&#160;million and $0.2&#160;million of interest income related to interest generated from the Company&#x2019;s cash and cash equivalents balances, respectively. &lt;/div&gt;&lt;/div&gt; </ck0001755237:InterestAndOtherIncomePolicyPolicyTextBlock>
    <us-gaap:InterestAndOtherIncome
      contextRef="P01_01_2025To12_31_2025_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-46865"
      unitRef="Unit_USD">100000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="P01_01_2024To12_31_2024_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-46866"
      unitRef="Unit_USD">200000</us-gaap:InterestAndOtherIncome>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29286"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company considers events or transactions that have occurred after the balance sheet date of December&#160;31, 2025, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K.&lt;/div&gt; See Note 12, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt; </us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29293"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December&#160;31, 2025 and 2024, that had a material effect on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2025, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2025-05,&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326), which requires incremental disclosures on estimating expected credit losses. The Company will adopt this guidance beginning with its annual report for fiscal 2027. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 10pt; text-align: left; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-07,&lt;/div&gt; Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company adopted this guidance beginning with its annual report for fiscal 2025 and interim periods thereafter on a retrospective basis. The adoption did not have a material effect on the consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09,&lt;/div&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09&lt;/div&gt; requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. For entities other than PBEs, the requirements will be effective for annual periods beginning after December&#160;15, 2025. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December&#160;31, 2025 and continuing to provide the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-ASU&lt;/div&gt; disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December&#160;31, 2025, the Company adopted this new ASU and it only impacts the Company&#x2019;s income tax disclosures with no impact to its operations, cash flows, or financial condition. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#x2019;s consolidated financial statements upon adoption. &lt;/div&gt;&lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29329"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;3. Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December&#160;31, 2025 and December&#160;31, 2024 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 60%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2024:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the year ended December&#160;31, 2025 and 2024, there were no transfers between levels. The fair value of the Company&#x2019;s cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company believes the carrying amounts of its accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair value due to the &lt;div style="display:inline;"&gt;short-term &lt;/div&gt;nature of these amounts. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29332"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December&#160;31, 2025 and December&#160;31, 2024 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 60%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2024:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-46868"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-46869"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-46870"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-46871"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-46872"
      unitRef="Unit_USD">3025000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-46873"
      unitRef="Unit_USD">3025000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-46874"
      unitRef="Unit_USD">3025000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-46875"
      unitRef="Unit_USD">3025000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29700"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;4. Other Investment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On July&#160;28, 2023, the Company closed the transactions contemplated by the Asset Purchase Agreement receiving proceeds of $8.0&#160;million as cash consideration, approximately $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 programs for the period between signing and closing of the transaction, and 10% of all of Tisento Parent&#x2019;s outstanding equity securities which fair value was determined to be $5.3&#160;million at the time of closing. The Company&#x2019;s investment in Tisento Parent does not provide it with significant influence over Tisento Parent. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company has determined that the Company&#x2019;s investment in Tisento Parent is an equity security, whereby such investment does not give the Company a controlling financial interest or significant influence over the investee.&#160;Further, the Company assessed the accounting for its investment in Tisento Parent in accordance &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;with&#160;ASC&#160;810-10,&#160;Consolidation&#x2014;Overall.&#160;After&lt;/div&gt; determining that no scope exception applies under the guidance &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;of&#160;ASC&#160;810-10-15-12&#160;and&#160;ASC&#160;810-10-15-17,&#160;the&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; Company&#160;concluded that it has a variable interest in Tisento Parent through its investment in Tisento Parent common stock. Tisento Parent does not have sufficient equity to finance its activities without additional subordinated financial support as Tisento Parent is a startup entity in its early stages of raising funds and will require significant capital to advance its programs to commercial stage. Therefore, the Company concluded that its investment in Tisento Parent is a variable interest entity (&#x201c;VIE&#x201d;) in accordance &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;with&#160;ASC&#160;810-10-15-14(a)&#160;and&#160;is&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; subject to potential consolidation under the VIE model. However, all activities that most significantly impact Tisento Parent and its subsidiary&#x2019;s economic performance are directed by the Tisento Parent board and the board approves decisions by a simple majority. Based on the board composition, the Company determined that no one party has control over the Tisento Parent board and power is not shared because the activities that most significantly affect Tisento Parent and its subsidiary&#x2019;s economic performance do not require the consent of all of the parties. Rather, all decisions are made by a simple majority vote of the Tisento Parent board. Therefore, because the Company controls no director of Tisento Parent, the Company cannot unilaterally direct any of the activities that most significantly impact Tisento Parent and its subsidiary&#x2019;s economic performance. Accordingly, the Company does not hold a controlling financial interest in Tisento Parent. Because both criteria (a)&#160;and (b)&#160;above have to be met for the application of the guidance &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in&#160;ASC&#160;810-10-25-44B&#160;and&#160;criteria&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; (a)&#160;has not been met, The Company concluded that it should not consolidate Tisento under the VIE model. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Accordingly, the Company has accounted for the investment as a financial instrument without a readily determinable fair value. Such investment is recorded using the measurement alternative for investments without readily determinable fair values, whereby the investment is measured at cost less any impairment recorded or adjustments for observable price changes. An impairment loss is recognized in the consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of December&#160;31, 2025, no impairment loss was recognized. The Company considers the cost of the investment to be the maximum exposure to loss as a result of its involvement with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-affiliated&lt;/div&gt; entity. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The initial fair value of the investment in Tisento Parent was determined by reference to the risk-adjusted net assets value using the discounted cash flow method. The estimated net assets value of Tisento Parent includes the cash generated/used from the operations and the proceeds from equity financing. Valuations were derived by reference to observable valuation measures for comparable companies or transactions, including weighted average cost of capital (21% to 23%), terminal decline rate (25% to 75%) and the discount rate referenced by a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-year&lt;/div&gt; treasury rate of 4.01%. &lt;/div&gt; </us-gaap:InvestmentTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-46877"
      unitRef="Unit_USD">8000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:OperatingExpenses
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-46878"
      unitRef="Unit_USD">2400000</us-gaap:OperatingExpenses>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      id="ixv-46879"
      unitRef="Unit_pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ck0001755237:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1
      contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-5"
      id="ixv-46880"
      unitRef="Unit_USD">5300000</ck0001755237:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46881"
      unitRef="Unit_USD">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_MinimumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-46882"
      unitRef="Unit_pure">0.21</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_MaximumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-46883"
      unitRef="Unit_pure">0.23</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_MinimumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-46884"
      unitRef="Unit_pure">0.25</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_MaximumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-46885"
      unitRef="Unit_pure">0.75</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_TreasuryRateMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-46886"
      unitRef="Unit_pure">0.0401</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29734"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;5. Accrued Expenses and Other Current Liabilities &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Employee compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29737"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Employee compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46887"
      unitRef="Unit_USD">143000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46888"
      unitRef="Unit_USD">220000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46889"
      unitRef="Unit_USD">13000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46890"
      unitRef="Unit_USD">33000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46891"
      unitRef="Unit_USD">38000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46892"
      unitRef="Unit_USD">30000</us-gaap:OtherSundryLiabilitiesCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-46893"
      unitRef="Unit_USD">194000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-46894"
      unitRef="Unit_USD">283000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29862"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Funding Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company may enter into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company&#x2019;s option and do not have any significant cancellation penalties. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Guarantees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#x2019;s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of December&#160;31, 2025 or December&#160;31, 2024. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Separation Benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As part of the separation benefit of the former Chief Financial Officer, the Company paid $0.1&#160;million each in May 2024 and August 2024. The Company has no further separation benefits obligation as of December&#160;31, 2025 and 2024. &lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-46895"
      unitRef="Unit_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2025"
      decimals="0"
      id="ixv-46896"
      unitRef="Unit_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SeveranceCosts1
      contextRef="P08_01_2024To08_31_2024"
      decimals="-5"
      id="ixv-46897"
      unitRef="Unit_USD">100000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="P05_01_2024To05_31_2024"
      decimals="-5"
      id="ixv-46898"
      unitRef="Unit_USD">100000</us-gaap:SeveranceCosts1>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-46899"
      unitRef="Unit_USD">0</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-46900"
      unitRef="Unit_USD">0</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29882"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;7. Share-based Compensation Plans &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (&#x201c;2019 ESPP&#x201d;) and the 2019 Equity Incentive Plan (&#x201c;2019 Equity Plan&#x201d;). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options, restricted stock awards (&#x201c;RSAs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cyclerion also mirrored two of Ironwood Pharmaceuticals, Inc. (&#x201c;Ironwood&#x201d;) existing plans, the Amended and Restated 2005 Stock Incentive Plan (&#x201c;2005 Equity Plan&#x201d;) and the Amended and Restated 2010 Employee, &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Director and Consultant Equity Incentive Plan (&#x201c;2010 Equity Plan&#x201d;). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pro-rata&lt;/div&gt; share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table provides share-based compensation reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2025 and 2024 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;534&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Stock options granted under the Company&#x2019;s equity plans generally have a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ten-year&lt;/div&gt; term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of stock option activity for the year ended December&#160;31, 2025 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 56%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Average&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&lt;br/&gt; thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;335,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;158.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled or forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(62,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;140.44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;297,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;149.73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;232,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;187.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the years ended December&#160;31, 2025 and 2024, the Company granted stock options to purchase an aggregate of 25,000 shares and 55,849 shares, respectively, at weighted average grant date fair values per option share of $2.14 and $2.80 respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;There were no options exercised during the year ended December&#160;31, 2025 and 2024. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of December&#160;31, 2025, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options held by the Company&#x2019;s employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employees&lt;/div&gt; is $0.1&#160;million and the weighted average period over which that expense is expected to be recognized is 3.03 years. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion during the years ended December&#160;31, 2025 and 2024 were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected option term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;141.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;111.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;For the years ended December&#160;31, 2025 and 2024, expected volatility was estimated using an average of the historical volatility of the common stock of a group of similar companies that were publicly traded. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has granted certain employees performance-based options to purchase shares of common stock. These options are subject to performance-based milestone vesting. During the year ended December&#160;31, 2025 and 2024, there were no shares that vested as a result of performance milestone achievements. No&#160;share-based compensation expense related to these performance-based options was recognized during the years ended December&#160;31, 2025, and 2024, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted Stock Awards &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No RSA was granted during the year ended December&#160;31, 2025. The Company granted 65,000&#160;RSAs during the year ended December&#160;31, 2024. The fair value of all RSAs is based on the market value of the Company&#x2019;s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of RSA activity for the years ended December&#160;31, 2025 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;164,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(60,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;104,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2025, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested RSAs held by the Company&#x2019;s directors is $0.2&#160;million and the weighted average period over which that expense is expected to be recognized is 1.69 years. &lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-29909">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table provides share-based compensation reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2025 and 2024 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;534&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2025To12_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-46902"
      unitRef="Unit_USD">29000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-46903"
      unitRef="Unit_USD">91000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2025To12_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-46904"
      unitRef="Unit_USD">412000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-46905"
      unitRef="Unit_USD">534000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46906"
      unitRef="Unit_USD">441000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46907"
      unitRef="Unit_USD">625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-30020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of stock option activity for the year ended December&#160;31, 2025 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 56%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Average&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&lt;br/&gt; thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;335,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;158.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled or forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(62,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;140.44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;297,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;149.73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;232,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;187.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-46908"
      unitRef="Unit_shares">335448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46909"
      unitRef="Unit_USD_per_Share">158.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-46910">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-46911"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-46912"
      unitRef="Unit_shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46913"
      unitRef="Unit_USD_per_Share">2.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46914"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46915"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46916"
      unitRef="Unit_shares">62686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46917"
      unitRef="Unit_USD_per_Share">140.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-46918"
      unitRef="Unit_shares">297762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46919"
      unitRef="Unit_USD_per_Share">149.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-46920">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-46921"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46922"
      unitRef="Unit_shares">232385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46923"
      unitRef="Unit_USD_per_Share">187.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-46924">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-46925"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-46926"
      unitRef="Unit_shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-46927"
      unitRef="Unit_shares">55849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46928"
      unitRef="Unit_USD_per_Share">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46929"
      unitRef="Unit_USD_per_Share">2.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-6"
      id="ixv-46930"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-6"
      id="ixv-46931"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-46932"
      unitRef="Unit_USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-46933">P3Y10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-30323">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion during the years ended December&#160;31, 2025 and 2024 were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected option term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;141.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;111.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="4"
      id="ixv-46935"
      unitRef="Unit_pure">0.0379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="4"
      id="ixv-46936"
      unitRef="Unit_pure">0.0364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-46937"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-46938"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2025To12_31_2025" id="ixv-46939">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2024To12_31_2024" id="ixv-46940">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="4"
      id="ixv-46941"
      unitRef="Unit_pure">1.4107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="4"
      id="ixv-46942"
      unitRef="Unit_pure">1.1197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2024To12_31_2024_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46943"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2025To12_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-46944"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <ck0001755237:ShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-46945"
      unitRef="Unit_USD">0</ck0001755237:ShareBasedCompensationExpense>
    <ck0001755237:ShareBasedCompensationExpense
      contextRef="P01_01_2025To12_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-46946"
      unitRef="Unit_USD">0</ck0001755237:ShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-46947"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-46948"
      unitRef="Unit_shares">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-30415">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of RSA activity for the years ended December&#160;31, 2025 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;164,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(60,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;104,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-46949"
      unitRef="Unit_shares">164174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46950"
      unitRef="Unit_USD_per_Share">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46951"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46952"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46953"
      unitRef="Unit_shares">60096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46954"
      unitRef="Unit_USD_per_Share">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46955"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46956"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-46957"
      unitRef="Unit_shares">104078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-46958"
      unitRef="Unit_USD_per_Share">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-46959"
      unitRef="Unit_USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2025To12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      id="ixv-46960">P1Y8M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-30556">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;8. Loss per share &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,057&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average shares used in calculating net loss per share &#x2014; basic and diluted (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,518&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss per share &#x2014; basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company excludes potential shares of common stock related to Preferred Stock, stock options and RSAs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. The following table sets forth potential shares that were considered anti-dilutive for the years ended December&#160;31, 2025 and 2024: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;351,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;351,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;297,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;335,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;RSAs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;104,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;164,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;752,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;850,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-30559">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,057&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average shares used in calculating net loss per share &#x2014; basic and diluted (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,518&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss per share &#x2014; basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46961"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46962"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46963"
      unitRef="Unit_shares">3181000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46964"
      unitRef="Unit_shares">3181000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46965"
      unitRef="Unit_shares">2518000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46966"
      unitRef="Unit_shares">2518000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-46967"
      unitRef="Unit_USD_per_Share">-1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-46968"
      unitRef="Unit_USD_per_Share">-1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-46969"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-46970"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-46971">The following table sets forth potential shares that were considered anti-dilutive for the years ended December&#160;31, 2025 and 2024: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;351,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;351,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;297,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;335,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;RSAs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;104,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;164,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;752,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;850,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46972"
      unitRef="Unit_shares">351037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-46973"
      unitRef="Unit_shares">351037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-46974"
      unitRef="Unit_USD">297762000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-46975"
      unitRef="Unit_USD">335448000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-46976"
      unitRef="Unit_USD">104078000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-46977"
      unitRef="Unit_USD">164174000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46978"
      unitRef="Unit_USD">752877000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46979"
      unitRef="Unit_USD">850659000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-30810">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9. Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The components of net income (loss) before income tax expense are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Domestic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows after adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; on a retrospective basis&#160;(in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Percent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Percent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pretax loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;US Federal Statutory Tax Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(741&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign tax effects&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-deductible&lt;/div&gt; items&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;571&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-16.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-2.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-4.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-18.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-align: left; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s effective tax rate differs from the statutory rate primarily due to continued losses and the maintenance of a full valuation allowance on deferred tax assets, resulting in zero income tax expense for the period. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets (liabilities) consist of the following as of December&#160;31, 2025 and 2024 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;57,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;53,281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Capitalized research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;12,370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;83,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;83,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has evaluated the positive and negative evidence bearing upon the possible realization of its deferred tax assets. Management has considered the Company&#x2019;s history of operating losses, in addition to the expected timing of the reversal of existing temporary differences and concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company will not realize the benefit of its deferred tax assets. Accordingly, the net deferred tax assets have been fully reserved at December&#160;31, 2025 and December&#160;31, 2024. Management reevaluates the positive and negative evidence on a quarterly basis. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The valuation allowance increased by approximately $0.2&#160;million during the year ended December&#160;31, 2025 primarily due to increases in capitalized research and development expenses, net operating losses, tax credit carryforwards and deferred tax assets related to share-based compensation. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;At December&#160;31, 2025 and 2024, Cyclerion has federal net operating loss carryforwards of approximately $211&#160;million and $195&#160;million, respectively, to offset future federal taxable income that will be carried forward indefinitely until utilized. As of December&#160;31, 2025 and 2024, Cyclerion had state net operating loss carryforwards of approximately $212&#160;million and $196&#160;million, respectively, to offset future state taxable income, which will begin to expire in 2039 and will continue to expire through 2045. Cyclerion also had tax credit carryforwards of approximately $10.8&#160;million as of December&#160;31, 2025, to offset future federal and state income taxes. Federal credits begin to expire in 2039 and will continue to expire through 2044. State credits begin to expire in 2034 and continue through 2039. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s ability to use its operating loss carryforwards and tax credits to offset future taxable income could be subject to restrictions under Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended (the &#x201c;Internal Revenue Code&#x201d;). These potential restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur. Changes in stock ownership may occur that would create these limitations on the Company&#x2019;s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has not as yet conducted a study of its research and development credit carry forwards. This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits, &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or statements of operations if an adjustment were required. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon audit, taxing authorities may challenge all or part of an uncertain income tax position. While Cyclerion has no history of tax audits since its inception on a standalone basis, it may be subject to tax audits by federal and state taxing authorities in the future. Accordingly, Cyclerion regularly assesses the outcome of potential examinations in each of the taxing jurisdictions when determining the adequacy of the amount of unrecognized tax benefit recorded. Cyclerion had no unrecognized tax benefits as of December&#160;31, 2025 and 2024. Cyclerion will recognize interest and penalties, if any, related to uncertain tax positions in income tax expense. As of December&#160;31, 2025 and 2024, no interest or penalties have been accrued. There are no current federal or state income tax audits in progress. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-30813">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The components of net income (loss) before income tax expense are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Domestic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46980"
      unitRef="Unit_USD">-3528000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46981"
      unitRef="Unit_USD">-3061000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46982"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46983"
      unitRef="Unit_USD">3000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46984"
      unitRef="Unit_USD">-3528000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46985"
      unitRef="Unit_USD">-3058000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-30921">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows after adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; on a retrospective basis&#160;(in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Percent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Percent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pretax loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;US Federal Statutory Tax Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(741&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign tax effects&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-deductible&lt;/div&gt; items&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;571&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-16.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-2.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-4.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-18.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46986"
      unitRef="Unit_USD">-3528000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46987"
      unitRef="Unit_USD">-3058000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46988"
      unitRef="Unit_USD">-741000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="3"
      id="ixv-46989"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46990"
      unitRef="Unit_USD">-642000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-46991"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46992"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-46993"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46994"
      unitRef="Unit_USD">-1000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-46995"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-46996"
      unitRef="Unit_USD">571000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="3"
      id="ixv-46997"
      unitRef="Unit_pure">-0.162</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-46998"
      unitRef="Unit_USD">88000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-46999"
      unitRef="Unit_pure">-0.029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-47000"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-47001"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-47002"
      unitRef="Unit_USD">11000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-47003"
      unitRef="Unit_pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-47004"
      unitRef="Unit_USD">170000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2025To12_31_2025"
      decimals="3"
      id="ixv-47005"
      unitRef="Unit_pure">-0.048</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-47006"
      unitRef="Unit_USD">566000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-47007"
      unitRef="Unit_pure">-0.185</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-47008"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2025To12_31_2025"
      decimals="3"
      id="ixv-47009"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-47010"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-47011"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-31212">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets (liabilities) consist of the following as of December&#160;31, 2025 and 2024 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;57,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;53,281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Capitalized research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;12,370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;83,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;83,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-47013"
      unitRef="Unit_USD">57618000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-47014"
      unitRef="Unit_USD">53281000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-47015"
      unitRef="Unit_USD">10385000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-47016"
      unitRef="Unit_USD">10383000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-47017"
      unitRef="Unit_USD">6500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-47018"
      unitRef="Unit_USD">7122000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-47019"
      unitRef="Unit_USD">8867000</ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-47020"
      unitRef="Unit_USD">12370000</ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-47021"
      unitRef="Unit_USD">20000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-47022"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-47023"
      unitRef="Unit_USD">83390000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-47024"
      unitRef="Unit_USD">83156000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-47025"
      unitRef="Unit_USD">83390000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-47026"
      unitRef="Unit_USD">83156000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-47027"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-47028"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2025To12_31_2025"
      decimals="-5"
      id="ixv-47029"
      unitRef="Unit_USD">200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-6"
      id="ixv-47030"
      unitRef="Unit_USD">211000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-6"
      id="ixv-47031"
      unitRef="Unit_USD">195000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-6"
      id="ixv-47032"
      unitRef="Unit_USD">212000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-6"
      id="ixv-47033"
      unitRef="Unit_USD">196000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OtherInformationPertainingToIncomeTaxes
      contextRef="P01_01_2025To12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-47034">begin to expire in 2039 and will continue to expire through 2045</us-gaap:OtherInformationPertainingToIncomeTaxes>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2025"
      decimals="-5"
      id="ixv-47035"
      unitRef="Unit_USD">10800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OtherInformationPertainingToIncomeTaxes
      contextRef="P01_01_2025To12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-47036">Federal credits begin to expire in 2039 and will continue to expire through 2044. State credits begin to expire in 2034 and continue through 2039</us-gaap:OtherInformationPertainingToIncomeTaxes>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-47038"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-47039"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-47040"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-47041"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-31459">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;10. Defined Contribution Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has established a defined contribution &lt;div style="-sec-ix-hidden:hidden162598875;display:inline;"&gt;401(k) Savings Plan&lt;/div&gt; which allows eligible employees to contribute from 1% to 100% of their compensation, subject to certain IRS limits. The Company&#x2019;s contributions to the plan are at the sole discretion of the board of directors. Currently, the Company provides a matching contribution of 75% of the employee&#x2019;s contributions, up to $6,000 annually. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Included in compensation expense is de minimis related to the defined contribution 401(k) Savings Plan for the years ended December&#160;31, 2025 and 2024, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="P01_01_2025To12_31_2025_MinimumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-47042"
      unitRef="Unit_pure">0.01</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-47043"
      unitRef="Unit_pure">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="P01_01_2025To12_31_2025"
      decimals="INF"
      id="ixv-47044"
      unitRef="Unit_pure">0.75</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <ck0001755237:DefinedContributionPlanEmployerMatchingContributionMaximum
      contextRef="P01_01_2025To12_31_2025"
      decimals="INF"
      id="ixv-47045"
      unitRef="Unit_USD">6000</ck0001755237:DefinedContributionPlanEmployerMatchingContributionMaximum>
    <ck0001755237:LicenseAgreementsTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-31467">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;11. License and Option Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent License Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;19, 2025, the Company and MIT entered into a Patent License Agreement (the &#x201c;MIT License Agreement&#x201d;) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the MIT License Agreement, the Company paid a nominal upfront license fee and patent reimbursement fee. Thereafter, the Company is also required to pay MIT a nominal annual license maintenance fee. This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to royalties earned during the same calendar year, if any. License maintenance fees paid in excess of royalties due in such calendar year shall not be creditable to amounts due for future years. Under the terms of the MIT License Agreement, MIT will be eligible to receive up to $4.4&#160;million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products as set forth in the MIT License Agreement. Further, the Company is required to pay MIT varying percentages of income received as consideration for any sublicenses granted pursuant to the MIT License Agreement depending on the circumstances of the sublicense and the development milestones of sublicensed products. The term of the MIT License Agreement will expire in its entirety upon the expiration of certain patent rights for the licensed patents, unless earlier terminated by the parties in accordance with the terms of the MIT License Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company recorded research and development expense of $0.1&#160;million for the year ended December&#160;31, 2025, which consisted of upfront fees, patent reimbursement fees and transaction costs related to the license. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Akebia License Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On June&#160;3, 2021, the Company and Akebia entered into a License Agreement (the &#x201c;Akebia License Agreement&#x201d;) relating to the exclusive worldwide license by the Company to Akebia of its rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the &#x201c;Products&#x201d;). Pursuant to the Akebia License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Akebia paid a $3.0&#160;million &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;up-front&lt;/div&gt; payment to the Company upon signing of the License Agreement. On December&#160;13, 2024, the Company and Akebia entered into Amendment #1 to the License Agreement (the &#x201c;2024 Amendment&#x201d;) to the original License Agreement between the parties dated June&#160;3, 2021. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under the terms of the 2024 Amendment, Akebia paid $1.75&#160;million in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million was paid in September 2025. In addition, Akebia has agreed to assume control of the preparation, filing, prosecution and maintenance of certain Cyclerion patents, and the expenses associated therewith, at an earlier date than as originally agreed between the parties. The parties have agreed to the reduction of certain development milestones and the increase of certain royalty rates on net sales and sublicense income. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#x201c;FSGS&#x201d;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to the Company and which was received in February 2026. Pursuant to the terms of the Akebia License Agreement, as amended, Cyclerion is eligible to receive additional potential future development, regulatory, and commercialization milestone payments up to $557.5&#160;million in total, and Akebia will pay Cyclerion tiered royalties ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-single&lt;/div&gt; digit to twenty percent of net sales. Cyclerion&#x2019;s obligations to deliver certain drug products have also ceased. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Akebia License Agreement, the Company determined the Akebia License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the Akebia License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company determined that the grant of license to its patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-evaluate&lt;/div&gt; the probability of achievement of the milestones and any related constraints each reporting period. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Akebia Material Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;3, 2025, the Company and Akebia entered into a Material Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) relating to the purchase of additional development materials (the &#x201c;Additional Development Materials&#x201d;) by Akebia for Akebia&#x2019;s use pursuant to the Akebia License Agreement. Akebia paid $0.8&#160;million to the Company for the purchase during the year ended December&#160;31, 2025 and the Additional Development Materials were delivered to Akebia as of December&#160;31, 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company determined the Purchase Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the Akebia License Agreement or the Amendment. The delivery of the Additional Development Materials by the Company represents a single performance obligation and consideration was recognized upon delivery. The Company recognized revenue of $0.8&#160;million during the year ended December&#160;31, 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;&lt;a href="#toc" style="null;text-indent: 0px;"&gt;Table of Contents&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Option Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#x201c;Option Agreement&#x201d;) with a third party (the &#x201c;Optionee&#x201d;), pursuant to which the Optionee had an option (the &#x201c;Option&#x201d;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which option period was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. &lt;/div&gt;&lt;/div&gt;</ck0001755237:LicenseAgreementsTextBlock>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="P09_19_2025To09_19_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47046"
      unitRef="Unit_USD">4400000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2025To12_31_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47047"
      unitRef="Unit_USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P06_03_2021To06_03_2021_AkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47049"
      unitRef="Unit_USD">3000000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P06_03_2021To06_03_2021_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-47050"
      unitRef="Unit_USD">1750000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_01_2024To12_31_2024_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-47051"
      unitRef="Unit_USD">1250000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:AdditionalUpFrontPayment
      contextRef="P01_01_2025To09_30_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47052"
      unitRef="Unit_USD">500000</ck0001755237:AdditionalUpFrontPayment>
    <ck0001755237:DevelopmentMilestonePayment
      contextRef="P02_01_2026To02_28_2026_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-47053"
      unitRef="Unit_USD">1000000</ck0001755237:DevelopmentMilestonePayment>
    <ck0001755237:CommercializationMilestonePayments
      contextRef="P01_01_2025To12_31_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47054"
      unitRef="Unit_USD">557500000</ck0001755237:CommercializationMilestonePayments>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47055"
      unitRef="Unit_USD">800000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47056"
      unitRef="Unit_USD">800000</us-gaap:Revenues>
    <ck0001755237:OptionFee
      contextRef="P08_01_2024To08_31_2024"
      decimals="0"
      id="ixv-47058"
      unitRef="Unit_USD">150000</ck0001755237:OptionFee>
    <ck0001755237:OptionAdditionalFee
      contextRef="P07_22_2024To07_22_2024"
      decimals="0"
      id="ixv-47059"
      unitRef="Unit_USD">80000</ck0001755237:OptionAdditionalFee>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-31536">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;12. Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On January&#160;6, 2026, the Company sold 405,000 shares of common stock under the Sales Agreement for net proceeds of approximately $0.8&#160;million. The Company exhausted all sales under the 2025 Shelf. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;3, 2026, the Company and the Medsteer, SAS (&#x201c;Medsteer&#x201d;) entered into a Collaboration and Option Agreement (the &#x201c;Collaboration Agreement&#x201d;) pursuant to which Medsteer granted to the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(i)&#160;a&#160;non-exclusive,&#160;worldwide,&lt;/div&gt; royalty-free, sublicensable license of certain of Medsteer&#x2019;s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii)&#160;an exclusive option (the &#x201c;Option&#x201d;), exercisable at the Company&#x2019;s sole discretion, to obtain an exclusive, worldwide, royalty-bearing, sublicensable license of certain of Medsteer&#x2019;s technology, software and intellectual property to develop or commercialize licensed products in any field of use except for sedation regulation for patients undergoing major surgery, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in&#160;multi-bed&#160;or&lt;/div&gt; intensive unit wards, or in the context of medical transport. The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an addition two years at the Company&#x2019;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Under the terms of the Collaboration Agreement, the Company will pay to Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer will be eligible to receive up to $3.7&#160;million upon the achievement of certain development, regulatory and sales milestone payments. Medsteer will also receive an annual royalty payment and royalties in a percentage in the low single digits based on future net sales of licensed products, subject to certain adjustments as set forth in the Collaboration Agreement. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-47060"
      unitRef="Unit_shares">405000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_06_2026To01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-47061"
      unitRef="Unit_USD">800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001755237:DebtInstrumentsOptionsExercisePeriod
      contextRef="P01_03_2026To01_03_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-47062">The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an addition two years at the Company&#x2019;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer.</ck0001755237:DebtInstrumentsOptionsExercisePeriod>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_03_2026To01_03_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-47063"
      unitRef="Unit_USD">3700000</ck0001755237:UpFrontPaymentReceived>
</xbrl>
